Table 2.

Univariate and multivariate Cox proportional hazard analyses with overall survival as endpoint.

	Patients, n	Events, n	Univariate HR (95% CI)	P value	Patients, n	Multivariate HR (95% CI)	P value
Gender
Male	525	227	1.00 (ref)			Not included
Female	593	262	1.05 (0.88–1.26)	0.575		Not included
Age
<60	194	50	1.00 (ref)		181	1.00 (ref)
60–74	434	178	1.78 (1.30–2.44)	<0.001	403	1.97 (1.42–2.73)	<0.001
≥75	490	261	2.51 (1.85–3.40)	<.0001	451	3.51 (2.56–4.83)	<0.001
Stage
I	188	37	1.00 (ref)		175	1.00 (ref)
II	439	138	1.73 (1.20–2.49)	0.003	408	1.43 (0.98–2.09)	0.061
III	301	144	3.08 (2.14–4.42)	<0.001	275	2.75 (1.90–4.00)	<0.001
IV	188	169	11.96 (8.34–17.14)	<.0001	177	3.29 (1.90–5.68)	<0.001
Localization
Right	454	202	1.00 (ref)			Not included
Left	350	164	1.06 (0.86–1.30)	0.602		Not included
Rectum	298	116	0.81 (0.65–1.02)	0.073		Not included
CIMP
CIMP−	912	392	1.00 (ref)		846	1.00 (ref)
CIMP+	206	97	1.18 (0.94–1.47)	0.144	189	1.89 (1.34–2.65)	<0.001
MLH1methylation
MLH1 unmeth	970	439	1.00 (ref)		899	1.00 (ref)
MLH1 meth	148	50	0.67 (0.50–0.90)	0.008	136	0.35 (0.23–0.56)	<0.001
MSI status
MSS	930	423	1.00 (ref)			Not included
MSI	179	61	0.69 (0.53–0.90)	0.007		Not included
BRAF
BRAF wt	882	379	1.00 (ref)		871	1.00 (ref)
BRAF mut	167	78	1.17 (0.91–1.49)	0.216	164	1.32 (0.92–1.9)	0.128
R status
R0	905	306	1.00 (ref)		836	1.00 (ref)
R1	24	10	1.39 (0.74–2.61)	0.304	24	1.28 (0.68–2.41)	0.451
R2	186	170	6.75 (5.55–8.21)	<0.001	175	4.30 (2.77–6.66)	<0.001

Meth, methylated; mut, mutation; unmeth, unmethylated; wt, wild type.